cetuximab

Open Access
Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
MARK T.J. VAN BUSSEL, NATHALIE BRAVENBOER, HUIB VAN ESSEN, PETUR SNAEBJORNSSON, NATASHA M. APPELMAN-DIJKSTRA, JAN HM SCHELLENS and FRANS L. OPDAM

Anticancer Research July 2025, 45 (7) 3137-3147; DOI: https://doi.org/10.21873/anticanres.17677
Open Access
Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer
FABIAN HUBER, ISIS WOLF, JONAS STORZ, SUSANNE SCHULTZE-SEEMANN, SUSAN LAUW, LUKAS KLEMENZ, ARKADIUSZ MIERNIK, CHRISTIAN GRATZKE, REINHARD BRÜCKNER and PHILIPP WOLF

Anticancer Research May 2024, 44 (5) 1837-1844; DOI: https://doi.org/10.21873/anticanres.16985
You have access
Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study
CHIH-CHIEN WU, CHIEN-CHOU SU, YU-HSUN CHEN, CHAO-WEN HSU, MENG-CHE HSIEH, YU-CHING CHANG, YUNG-CHANG WANG and YI-CHIA SU

Anticancer Research November 2023, 43 (11) 5127-5138; DOI: https://doi.org/10.21873/anticanres.16713
You have access
CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy
HIDEKO AKAGI, YUSAKU TANAKA, KOHEI WADA, MIANAMI TAKAHASHI, KOUDAI YOSHIDA and HIDEHARU DOMOTO

Anticancer Research June 2023, 43 (6) 2879-2884; DOI: https://doi.org/10.21873/anticanres.16458
You have access
Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
LOLA MACIA-RIVAS, CLARA LUZ FERNANDEZ-LAGUNA, CRISTINA ALVAREZ-ASTEINZA, IVAN MARAY, MONICA CARBAJALES-ALVAREZ and ANA LOZANO-BLAZQUEZ

Anticancer Research April 2023, 43 (4) 1681-1688; DOI: https://doi.org/10.21873/anticanres.16320
You have access
Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor
MASAKI YODA, KANAME SAKUMA, TOMOYUKI KII and AKIRA TANAKA

Anticancer Research September 2022, 42 (9) 4273-4283; DOI: https://doi.org/10.21873/anticanres.15927
You have access
Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma
GEORGIOS PETRAKIS, THEODORA MANTSO, MICHAIL I. KOUKOURAKIS, MIHALIS I. PANAYIOTIDIS and SOTIRIS BOTAITIS

Anticancer Research May 2022, 42 (5) 2363-2374; DOI: https://doi.org/10.21873/anticanres.15715
You have access
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII

Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
You have access
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
TOMOFUMI NARUSE, SOUICHI YANAMOTO, MITSUNOBU OTSURU, NOBUHIRO YAMAKAWA, TADAAKI KIRITA, YUKARI SHINTANI, TATSUSHI MATSUMURA, MASAYA OKURA, MASASHI SASAKI, YOSHIHIDE OTA, SHIN-ICHI YAMADA, HIROSHI KURITA, MASAHIRO UMEDA and JAPAN ORAL ONCOLOGY GROUP (JOOG)

Anticancer Research November 2021, 41 (11) 5785-5791; DOI: https://doi.org/10.21873/anticanres.15395
You have access
PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma
TOMOYUKI KII, KANAME SAKUMA and AKIRA TANAKA

Anticancer Research July 2021, 41 (7) 3363-3370; DOI: https://doi.org/10.21873/anticanres.15124

Main menu

User menu

Search

cetuximab

Pages